- 5 Adams JQ, Alexander AM. Alterations in cardiovascular physiology during labor. *Obstet Gynecol* 1958;12:542-9.
- 6 Maruta S. The observation of the maternal hemodynamics during labor and cesarean section. *Nippon Sanka Fujinka Gakkai Zasshi* 1982;34:776-84.
- 7 Lees MM, Scott DB, Kerr MG, Taylor SH. The circulatory effects of recumbent postural change in late pregnancy. *Clin Sci* 1967;32:453-65.
- 8 Goldberg SJ, Allen HD, Marx GR, Flinn CJ. *Doppler echocardiography*. Philadelphia: Lea & Febiger, 1985.
- 9 Robson SC, Dunlop W, Moore M, Hunter S. Combined Doppler and echocardiographic measurement of cardiac output: theory and application in pregnancy. *Br J Obstet Gynaecol* (in press).
- 10 Numerical Algorithms Group Limited. *Genstat manual. Part 1, release 4-01*. Oxford: NAG Ltd, 1983.
- 11 Pearson ES, Hartley HO. *Biometrika tables for statisticians*. London: Cambridge University Press, 1966.
- 12 Robson SC, Hunter S, Moore M, Dunlop W. Haemodynamic changes during the puerperium; a Doppler and M-mode echocardiographic study. *Br J Obstet Gynaecol* (in press).

- 13 Vorys N, Ullery JC, Hanusek GE. The cardiac output in various positions in pregnancy. *Am J Obstet Gynecol* 1961;82:1312-21.
- 14 Stewart WJ, Jiang L, Mich R, Pandian N, Guerrero JL, Weyman AE. Variable effects of changes in flow rate through the aortic, pulmonary and mitral valves on valve area and flow velocity: impact on quantitative Doppler flow calculations. *Journal of the American College of Cardiology* 1985;6:653-62.
- 15 Ueland K, Hansen JM. Maternal cardiovascular dynamics. II. Posture and uterine contractions. *Am J Obstet Gynecol* 1969;103:1-7.
- 16 Kerr MG. The mechanical effects of the gravid uterus in late pregnancy. *Journal of Obstetrics and Gynaecology of the British Commonwealth* 1965;72:513-29.
- 17 Robson SC, Dunlop W, Hunter S. Haemodynamic changes during the early puerperium. *Br Med J* 1987;294:1065.
- 18 Edwards EM. The blood pressure in normal labour. *Journal of Obstetrics and Gynaecology of the British Commonwealth* 1958;15:367-70.

(Accepted 15 September 1987)

SHORT REPORTS

Cyclical sequential hormonchemotherapy in advanced breast cancer

Endocrine treatment or chemotherapy is widely used for patients with breast cancer, and the response rate remains more or less constant at about 30-40%. Using hormonal treatment to render the cancer cells more susceptible to cytotoxic chemotherapy was proposed by Lippman¹ and Allegra *et al.*² We report using oestrogen at a physiological concentration to bring stem cells out of the resting phase and to stimulate cell division into partial synchrony. High dose progesterone is then given, which, by reducing the receptor state of the cancer cells, is designed to enhance their susceptibility to the subsequent cytotoxic chemotherapy. This was administered cyclically and sequentially at three week intervals in accordance with the stem cell kinetic data of Skipper³ and Hill.⁴

Patients, methods, and results

Forty women presenting with advanced breast cancer were treated with our regimen. All were postmenopausal (mean age 63 (SD 11) years), with the exception of two patients aged 30 and 36. The diagnosis of advanced breast cancer

Comment

The results of this study in which women with advanced metastatic breast cancer were treated with three double cycles of sequential hormonchemotherapy are very encouraging. Over 90% of the women showed some degree of objective response. Furthermore, the 16 (47%) patients who obtained a complete response by established criteria⁵ had a disease free interval of 22 months. The response to hormonal treatment alone in unselected patients is usually about 30%, which may improve to about 60% in patients selected on the basis of their oestrogen receptor state. The response to chemotherapy may be higher but is usually between 30% and 60%. The disease free interval in patients treated with either hormonal treatment or chemotherapy is usually less than one year.

As hormones and drugs are thought to act by different mechanisms and against different cell populations, we have combined hormonal treatment with chemotherapy. We have not, however, simply used these two forms of treatment in an adjuvant synchronous manner but have attempted to use the hormones in such a way as to bring the stem cells out of their resting phase and make them more susceptible to cytotoxic drugs: hence cyclical sequential hormonchemotherapy.

Our results suggest that using hormonal and cytotoxic treatment in a cyclical sequential combination may significantly improve the response rate compared with using either treatment alone and provides a useful prolongation of life.

Response in metastatic sites

Site	No	No (%) showing complete response	Mean duration (months)	No (%) showing partial response	Mean duration (months)	Overall response (%)
Advanced local disease or lymph node fixity, or both	17	7 (41)	22	8 (47)	6	89
Bone	8	2 (25)	23	6 (75)	5	100
Lung	6	2 (33)	21	3 (50)	7	83
Liver	7	1 (14)	24	5 (71)	6	85

was based on finding one or more of the following: metastases in bone (eight cases), lung (six), or liver (seven) or fixity of axillary lymph nodes (17) and large tumour size (mean 7.5 (SD 3.9) cm).

Patients received three double cycles of hormonchemotherapy. Hormonal treatment was initiated with ethinyloestradiol for one week (10 µg/day) followed by medroxyprogesterone acetate for two weeks (500 mg/day intramuscularly). At the end of the first three week period of hormonal treatment the patient received a bolus injection of vincristine (2 mg intravenously) and an infusion of doxorubicin (50 mg intravenously). The hormonal treatment was then repeated for a further three weeks—that is, one week of oestrogen, two weeks of progesterone—at the end of which an infusion of cyclophosphamide (500 mg), methotrexate (50 mg), and 5-fluorouracil (500 mg) was given. This constituted one double cycle, and patients received three of these cycles. Response to treatment was assessed according to criteria of the International Union Against Cancer.⁵

Thirty four of the 40 patients completed three double cycles of treatment. Of these, 16 showed a complete response, 15 a partial response, and only three no response, giving an overall response rate of 91%. The six patients who did not complete the treatment died of their disease before they had finished one cycle. The mean disease free interval for patients showing a complete response was 22.0 months and was significantly longer ($p < 0.05$) than the 11.6 months for partial responders.

The table shows the response by metastatic site together with the average duration of disease free interval for patients achieving a complete or partial response. The overall response at these sites approached 90%.

- 1 Lippman ME. Efforts to combine endocrine and chemotherapy in the management of breast cancer. Do two and two equal three? *Breast Cancer Res Treat* 1983;3:117-27.
- 2 Allegra JC, Woodcock TM, Richman SP, *et al.* A phase II trial of tamoxifen, Premarin, methotrexate and 5-fluorouracil in metastatic cancer. *Breast Cancer Res Treat* 1982;2:93-9.
- 3 Skipper HE. Kinetics of mammary tumor cell growth and implication for therapy. *Cancer* 1971;28:1479-99.
- 4 Hill BT. Experimental background to safer cancer chemotherapy. In: Price LA, Hill BT, Ghilchik MW, eds. *Safer cancer chemotherapy*. London: Baillière, Tindall, 1981:4-8.
- 5 Hayward JL, Carbone PP, Henson J-C, *et al.* Assessment of response to therapy in advanced breast cancer. *Eur J Cancer Clin Oncol* 1977;13:89-94.

(Accepted 9 September 1987)

The Breast Clinic, St Mary's Hospital, London W2 1NY
MARGARET W GHILCHIK, MS, FRCS, consultant surgeon
N A SHAIKH, FRCS, surgical registrar

Department of Chemical Pathology, St Mary's Hospital Medical School, London W2 1PG

P A BERANEK, MB, PHD, lecturer
M J REED, MSC, PHD, senior lecturer

Correspondence to: Mrs Ghilchik.